Advancing Novel Biotherapeutics Since 1995®
At Dyax, our patients are at the center of everything we do.
Dyax phage display technology is a rapid and robust research tool for generating highly specific potent binders to challenging therapeutic targets.
Dyax combines a strong foundation in hereditary angioedema (HAE) patient care with a commitment to product development.
Please see Full Prescribing Information, including Boxed Warning and Medication Guide on KALBITOR.com.
DX-2930 is a fully human monoclonal antibody inhibitor of active plasma kallikrein. It is an investigational drug candidate in development for the prevention of hereditary angioedema (HAE) attacks.